Protagonist Therapeutics Earnings
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 5, 2026
Fiscal period
Sep/2026
EPS estimate
$2.19
Protagonist Therapeutics earnings summary
Protagonist Therapeutics is scheduled to report Sep/2026 earnings on Nov 5, 2026, with analysts expecting EPS of $2.19. In its most recent report on Aug 5, 2026 (Q2 2026), PTGX posted EPS of $2.29. Revenue for the quarter was $213.5 million.
Across the last 16 reports, PTGX shares moved an average of 5.5% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
PTGX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $2.29 | — | +6.3% |
| May 5, 2026 | — | $0.05 | — | +2.8% |
| Feb 25, 2026 | — | $-0.69 | — | +0.0% |
| Nov 6, 2025 | — | $-0.62 | — | +6.4% |
| Aug 6, 2025 | — | $-0.55 | — | +9.8% |
| May 6, 2025 | — | $-0.19 | — | +3.5% |
| Feb 21, 2025 | — | $2.01 | — | -3.0% |
| Nov 7, 2024 | — | $-0.54 | — | -11.1% |
| Aug 6, 2024 | — | $-0.50 | — | +6.9% |
| May 7, 2024 | — | $3.26 | — | +8.9% |
| Feb 27, 2024 | — | $0.54 | — | -5.7% |
| Nov 2, 2023 | — | $-0.58 | — | -7.0% |
| Aug 3, 2023 | — | $-0.68 | — | -1.4% |
| May 4, 2023 | — | $-0.67 | — | +2.3% |
| Mar 15, 2023 | — | $-0.69 | — | -7.5% |
| Nov 8, 2022 | — | $-0.64 | — | -4.7% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.